Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing

1 Jun 2023

Abstract excerpt

There is overwhelming clinical and genetic evidence supporting the concept that low-density-lipoprotein cholesterol should be as low as possible for as long as possible in patients at very high cardiovascular risk. Despite the wide availability of effective lipid-lowering therapies, the majority of patients still fail to reach guideline-based lipid goals. Advances in novel approaches targeting PCSK9 (proprotein...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to Lipoproteins and Cardiovascular Health
Share to Viral Infections and Immunology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37259866
DOI: 10.1161/atvbaha.122.317963

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome EditingPMID 37259866Read ↗

Moving toward genome-editing therapies for cardiovascular diseasesSemantic proximity Read ↗

RNA Silencing in the Management of DyslipidemiasSemantic proximity Read ↗

CRISPR-Cas9 Targeting PCSK9: A Promising Therapeutic Approach for Atherosclerosis.Semantic proximity Read ↗

CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and OpportunitiesSemantic proximity Read ↗

PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.Semantic proximity Read ↗

Inclisiran—Silencing the Cholesterol, Speaking up the PrognosisSemantic proximity Read ↗

Gene therapy and genome editing for lipoprotein disordersSemantic proximity Read ↗

Advances in nucleic acid-targeted therapies for cardiovascular disease preventionSemantic proximity Read ↗

Gene Editing for the Treatment of HypercholesterolemiaSemantic proximity Read ↗

Gene-based therapy in lipid management: the winding road from promise to practiceSemantic proximity Read ↗

Is It Ever Wise to Edit Wild-Type Alleles? Engineered CRISPR Alleles Versus Millions of Years of Human Evolution.Semantic proximity Read ↗

Targeted Epigenetic Modulation Outperforms Nuclease- and Deaminase-Based Editing for Durable <i>Pcsk9</i> Silencing in a Clinically Relevant Delivery SystemSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.